Pulmonary hypertension: treprostinil safe and effective in the long term?

被引：0
|
作者：
Simon, Annika
机构：
来源：
PNEUMOLOGIE | 2024年 / 78卷 / 03期
关键词：
D O I：
10.1055/a-2196-8522
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Nachdem eine Therapie mit inhaliertem Trepostinil in der INCREASE-Studie mit Betroffenen einer pulmonalen Hypertonie mit interstitieller Lungenerkrankung uber 16 Wochen als sicher und wirksam bewertet werden konnte, stellt sich die Frage nach entsprechenden Effekten im Rahmen einer Langzeittherapie. Waxman et al. sind dieser Frage nachgegangen und haben eine offene Verlangerung dieser Studie initiiert.
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension
    Harutyunova, Satenik
    Benkamin, Nicola
    Eichstaedt, Christina
    Marra, Alberto Maria
    Xanthouli, Panagiota
    Egenlauf, Benjamin
    Gruenig, Ekkehard
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [22] Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension
    Sadushi-Kolici, Roela
    Skoro-Sajer, Nika
    Zimmer, Daniel
    Bonderman, Diana
    Schemper, Michael
    Klepetko, Walter
    Glatz, Jutta
    Jakowitsch, Johannes
    Lang, Irene M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (07): : 735 - 743
  • [23] Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
    White, R. James
    Parikh, Keyur
    Allen, Roblee
    Feldman, Jeremy
    Jerjez-Sanchez, Carlos
    Pan, Lei
    Keogh, Anne
    Vizza, C. Dario
    Shapiro, Shelley
    Gordon, Kathryn
    Broderick, Meredith
    Bartolome, Sonja
    PULMONARY CIRCULATION, 2020, 10 (04)
  • [24] Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
    Benza, Raymond L.
    Seeger, Werner
    McLaughlin, Vallerie V.
    Channick, Richard N.
    Voswinckel, Robert
    Tapson, Victor F.
    Robbins, Ivan M.
    Olschewski, Horst
    Rubin, Lewis J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (12): : 1327 - 1333
  • [25] Long-term safety and outcome of subcutaneous and intravenous treprostinil treatment in patients with severe chronic pulmonary hypertension
    Harutyunova, S.
    Benjamin, N.
    Eichstaedt, C.
    Marra, A. M.
    Xanthouli, P.
    Egenlauf, B.
    Gruenig, E.
    PNEUMOLOGIE, 2020, 74 : S125 - S125
  • [26] Subcutaneous treprostinil therapy in pulmonary arterial hypertension due to congenital heart diseases - A long term multicentre analysis
    Vachiery, JL
    Pavelescu, A
    Lang, IM
    Skoro, N
    Gomez-Sanchez, MA
    Escribano, P
    Naeije, R
    CIRCULATION, 2005, 112 (17) : U480 - U481
  • [27] Treprostinil in the treatment of pulmonary arterial hypertension
    Gomez Sanchez, Miguel Angel
    INSUFICIENCIA CARDIACA, 2008, 3 (02) : 102 - 104
  • [28] USE OF SUBCUTANEOUS TREPROSTINIL IN PEDIATRIC PULMONARY ARTERIAL HYPERTENSION - BRIDGE-TO-TRANSPLANT OR LONG-TERM TREATMENT?
    Ablonczy, L.
    PEDIATRIC TRANSPLANTATION, 2017, 21 : 11 - 11
  • [29] Treprostinil in the treatment of pulmonary arterial hypertension
    Feldman, Jeremy
    Habib, Naomi
    Fann, Jade
    Radosevich, John J.
    FUTURE CARDIOLOGY, 2020, 16 (06) : 547 - 558
  • [30] LONG-TERM SAFETY AND TOLERABILITY OF INHALED TREPROSTINIL IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE
    Waxman, Aaron B.
    Elwing, Jean M.
    Melendres-Groves, Lana
    Risbano, Michael G.
    Lenneman, Andrew J.
    Tapson, Victor F.
    Shen, Eric
    Smith, Peter
    Deng, C. Q.
    Nathan, Steven D.
    CHEST, 2022, 162 (04) : 2330A - 2332A
12345